How large is the anti-obesity drug market?

The anti-obesity drug market is valued at nearly $80 billion.

When did Novo Nordisk launch its Wegovy pill?

Novo Nordisk launched its Wegovy pill in January 2026.

What is the source of this information?

The source is a report from The Wall Street Journal.

Novo Nordisk Obesity Pill Leaves Lilly in the Dust

Novo Nordisk is pulling ahead in the oral obesity drug race, with its Wegovy pill capturing the vast majority of new prescriptions. Eli Lilly's Foundayo, launched in April, has only secured 11% of the market. The nearly $80 billion anti-obesity market is witnessing a surprising shift.

July 15, 2026

2 min read

Source: The Wall Street Journal

Key Numbers

lilly market share

11%

market size

80B

According to a report from The Wall Street Journal, the oral obesity drug market is heating up between Novo Nordisk and Eli Lilly. Since Lilly's Foundayo pill hit the market in April 2026, it has captured only 11% of new prescription volume, while Novo Nordisk's Wegovy pill, launched in January, commands the rest.

Market Details

The anti-obesity market is valued at nearly $80 billion, one of the fastest-growing segments in pharma. The latest weekly data shows a clear lead for Novo Nordisk, marking a remarkable turn of events.

Context

This development comes after expectations that Lilly would dominate the oral obesity space, especially given the success of its injectable Mounjaro/Zepbound. However, Wegovy's oral formulation appears to have gained stronger traction among patients and prescribers.

What It Means for Investors

While early, Novo Nordisk's current lead could impact revenue projections for both companies in the obesity segment. Investors should monitor market share trends in the coming months to assess long-term direction.

Frequently Asked Questions

Eli Lilly has captured 11% of new prescription volume for obesity pills since launching Foundayo in April 2026.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.